QuidelOrtho Corporation Logo

QuidelOrtho Corporation

QDEL

(1.5)
Stock Price

40,07 USD

-59.58% ROA

-45.2% ROE

-1.52x PER

Market Cap.

2.834.644.464,00 USD

81.71% DER

0% Yield

-65.64% NPM

QuidelOrtho Corporation Stock Analysis

QuidelOrtho Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

QuidelOrtho Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.89x), the stock offers substantial upside potential at a bargain price.

2 ROE

ROE in an average range (0.27%) suggests satisfactory profitability and decent utilization of shareholders' equity.

3 ROA

The stock's ROA (0.42%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 DER

The stock maintains a fair debt to equity ratio (53%), indicating a reasonable balance between the money it owes and the ownership it possesses.

5 Buffet Intrinsic Value

The company's stock seems undervalued (47.698) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

QuidelOrtho Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

QuidelOrtho Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

QuidelOrtho Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

QuidelOrtho Corporation Revenue
Year Revenue Growth
1985 9.500.000
1986 7.500.000 -26.67%
1987 6.100.000 -22.95%
1988 8.700.000 29.89%
1989 9.000.000 3.33%
1990 27.800.000 67.63%
1991 26.500.000 -4.91%
1992 27.700.000 4.33%
1993 28.400.000 2.46%
1994 31.100.000 8.68%
1995 34.500.000 9.86%
1996 41.900.000 17.66%
1997 45.700.000 8.32%
1998 47.200.000 3.18%
2000 68.351.000 30.94%
2001 74.055.000 7.7%
2002 76.273.000 2.91%
2003 95.105.000 19.8%
2004 78.691.000 -20.86%
2005 92.299.000 14.74%
2006 106.015.000 12.94%
2007 118.065.000 10.21%
2008 128.132.000 7.86%
2009 164.282.000 22%
2010 113.339.000 -44.95%
2011 158.603.000 28.54%
2012 155.741.000 -1.84%
2013 175.410.000 11.21%
2014 182.615.000 3.95%
2015 196.129.000 6.89%
2016 191.603.000 -2.36%
2017 277.743.000 31.01%
2018 522.285.000 46.82%
2019 534.890.000 2.36%
2020 1.661.668.000 67.81%
2021 1.698.551.000 2.17%
2022 3.266.000.000 47.99%
2023 2.976.000.000 -9.74%
2023 2.993.500.000 0.58%
2024 2.545.200.000 -17.61%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

QuidelOrtho Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 4.100.000 100%
1996 6.700.000 38.81%
1997 7.900.000 15.19%
1998 7.900.000 0%
2000 7.046.000 -12.12%
2001 6.203.000 -13.59%
2002 6.748.000 8.08%
2003 8.465.000 20.28%
2004 11.340.000 25.35%
2005 12.829.000 11.61%
2006 13.047.000 1.67%
2007 12.855.000 -1.49%
2008 11.147.000 -15.32%
2009 12.526.000 11.01%
2010 24.571.000 49.02%
2011 26.325.000 6.66%
2012 27.716.000 5.02%
2013 34.186.000 18.93%
2014 37.913.000 9.83%
2015 35.514.000 -6.76%
2016 38.672.000 8.17%
2017 33.644.000 -14.94%
2018 51.649.000 34.86%
2019 52.553.000 1.72%
2020 84.292.000 37.65%
2021 95.701.000 11.92%
2022 190.500.000 49.76%
2023 249.600.000 23.68%
2023 246.800.000 -1.13%
2024 225.200.000 -9.59%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

QuidelOrtho Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
2000 8.845.000 100%
2001 0 0%
2002 25.847.000 100%
2003 28.505.000 9.32%
2004 28.842.000 1.17%
2005 29.183.000 1.17%
2006 29.736.000 1.86%
2007 31.658.000 6.07%
2008 12.786.000 -147.6%
2009 16.783.000 23.82%
2010 18.471.000 9.14%
2011 22.798.000 18.98%
2012 20.640.000 -10.46%
2013 26.258.000 21.4%
2014 25.811.000 -1.73%
2015 29.447.000 12.35%
2016 27.062.000 -8.81%
2017 29.192.000 7.3%
2018 44.951.000 35.06%
2019 52.755.000 14.79%
2020 66.586.000 20.77%
2021 84.247.000 20.96%
2022 594.200.000 85.82%
2023 0 0%
2023 748.100.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

QuidelOrtho Corporation EBITDA
Year EBITDA Growth
1985 200.000
1986 -9.000.000 102.22%
1987 -1.700.000 -429.41%
1988 -2.400.000 29.17%
1989 1.400.000 271.43%
1990 -4.000.000 135%
1991 800.000 600%
1992 1.000.000 20%
1993 -2.800.000 135.71%
1994 -2.700.000 -3.7%
1995 1.800.000 250%
1996 800.000 -125%
1997 -200.000 500%
1998 -3.700.000 94.59%
2000 4.251.000 187.04%
2001 10.430.000 59.24%
2002 7.628.000 -36.73%
2003 21.654.000 64.77%
2004 7.369.000 -193.85%
2005 17.127.000 56.97%
2006 22.398.000 23.53%
2007 29.455.000 23.96%
2008 34.781.000 15.31%
2009 56.780.000 38.74%
2010 -6.068.000 1035.73%
2011 21.067.000 128.8%
2012 15.792.000 -33.4%
2013 14.207.000 -11.16%
2014 3.178.000 -347.04%
2015 11.594.000 72.59%
2016 4.634.000 -150.19%
2017 26.058.000 82.22%
2018 110.126.000 76.34%
2019 104.383.000 -5.5%
2020 1.064.020.000 90.19%
2021 915.622.000 -16.21%
2022 1.104.100.000 17.07%
2023 400.400.000 -175.75%
2023 703.500.000 43.08%
2024 343.200.000 -104.98%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

QuidelOrtho Corporation Gross Profit
Year Gross Profit Growth
1985 5.900.000
1986 -1.100.000 636.36%
1987 1.800.000 161.11%
1988 3.400.000 47.06%
1989 5.300.000 35.85%
1990 14.100.000 62.41%
1991 13.600.000 -3.68%
1992 14.500.000 6.21%
1993 14.600.000 0.68%
1994 16.900.000 13.61%
1995 20.600.000 17.96%
1996 24.700.000 16.6%
1997 24.600.000 -0.41%
1998 24.400.000 -0.82%
2000 31.848.000 23.39%
2001 38.784.000 17.88%
2002 38.006.000 -2.05%
2003 52.293.000 27.32%
2004 43.457.000 -20.33%
2005 55.198.000 21.27%
2006 61.197.000 9.8%
2007 69.492.000 11.94%
2008 77.926.000 10.82%
2009 109.064.000 28.55%
2010 60.732.000 -79.58%
2011 95.738.000 36.56%
2012 94.456.000 -1.36%
2013 108.434.000 12.89%
2014 108.435.000 0%
2015 124.441.000 12.86%
2016 118.189.000 -5.29%
2017 156.142.000 24.31%
2018 315.713.000 50.54%
2019 320.805.000 1.59%
2020 1.348.855.000 76.22%
2021 1.270.895.000 -6.13%
2022 1.936.000.000 34.35%
2023 1.472.400.000 -31.49%
2023 1.283.400.000 -14.73%
2024 894.000.000 -43.56%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

QuidelOrtho Corporation Net Profit
Year Net Profit Growth
1985 -100.000
1986 -8.100.000 98.77%
1987 -7.300.000 -10.96%
1988 -3.100.000 -135.48%
1989 -1.200.000 -158.33%
1990 -5.500.000 78.18%
1991 800.000 787.5%
1992 700.000 -14.29%
1993 -2.000.000 135%
1994 -4.100.000 51.22%
1995 600.000 783.33%
1996 3.500.000 82.86%
1997 1.100.000 -218.18%
1998 7.700.000 85.71%
2000 -5.846.000 231.71%
2001 854.000 784.54%
2002 1.291.000 33.85%
2003 19.651.000 93.43%
2004 -6.287.000 412.57%
2005 -9.259.000 32.1%
2006 21.718.000 142.63%
2007 13.631.000 -59.33%
2008 18.848.000 27.68%
2009 32.883.000 42.68%
2010 -11.271.000 391.75%
2011 7.633.000 247.66%
2012 4.993.000 -52.87%
2013 7.390.000 32.44%
2014 -7.074.000 204.47%
2015 -6.079.000 -16.37%
2016 -13.808.000 55.97%
2017 -8.165.000 -69.11%
2018 74.183.000 111.01%
2019 72.921.000 -1.73%
2020 810.287.000 91%
2021 704.200.000 -15.06%
2022 548.700.000 -28.34%
2023 -50.800.000 1180.12%
2023 -10.100.000 -402.97%
2024 -590.800.000 98.29%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

QuidelOrtho Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 -2 100%
1987 -2 0%
1988 -1 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 1 0%
2004 0 0%
2005 0 0%
2006 1 0%
2007 0 0%
2008 1 0%
2009 1 100%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 2 100%
2019 2 0%
2020 19 94.74%
2021 17 -18.75%
2022 10 -77.78%
2023 -1 0%
2023 0 0%
2024 -9 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

QuidelOrtho Corporation Free Cashflow
Year Free Cashflow Growth
1991 -5.100.000
1992 -7.900.000 35.44%
1993 -2.200.000 -259.09%
1994 -2.400.000 8.33%
1995 -900.000 -166.67%
1996 100.000 1000%
1997 2.500.000 96%
1998 -2.400.000 204.17%
2000 -1.562.000 -53.65%
2001 174.000 997.7%
2002 1.895.000 90.82%
2003 16.328.000 88.39%
2004 4.510.000 -262.04%
2005 -1.935.000 333.07%
2006 9.762.000 119.82%
2007 23.593.000 58.62%
2008 24.463.000 3.56%
2009 65.743.000 62.79%
2010 -20.770.000 416.53%
2011 26.195.000 179.29%
2012 -8.089.000 423.83%
2013 3.181.000 354.29%
2014 24.445.000 86.99%
2015 19.277.000 -26.81%
2016 -94.000 20607.45%
2017 10.199.000 100.92%
2018 104.656.000 90.25%
2019 107.256.000 2.42%
2020 564.836.000 81.01%
2021 513.145.000 -10.07%
2022 744.400.000 31.07%
2023 41.500.000 -1693.73%
2023 70.900.000 41.47%
2024 -133.200.000 153.23%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

QuidelOrtho Corporation Operating Cashflow
Year Operating Cashflow Growth
1991 -3.300.000
1992 1.000.000 430%
1993 -300.000 433.33%
1994 100.000 400%
1995 1.000.000 90%
1996 5.200.000 80.77%
1997 6.700.000 22.39%
1998 1.800.000 -272.22%
2000 1.806.000 0.33%
2001 5.874.000 69.25%
2002 6.158.000 4.61%
2003 18.822.000 67.28%
2004 9.948.000 -89.2%
2005 1.222.000 -714.08%
2006 20.731.000 94.11%
2007 27.342.000 24.18%
2008 28.941.000 5.53%
2009 72.843.000 60.27%
2010 -10.293.000 807.69%
2011 46.982.000 121.91%
2012 19.633.000 -139.3%
2013 25.682.000 23.55%
2014 35.686.000 28.03%
2015 36.309.000 1.72%
2016 11.815.000 -207.31%
2017 27.709.000 57.36%
2018 136.345.000 79.68%
2019 134.485.000 -1.38%
2020 629.763.000 78.65%
2021 805.869.000 21.85%
2022 885.300.000 8.97%
2023 41.500.000 -2033.25%
2023 280.200.000 85.19%
2024 -97.900.000 386.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

QuidelOrtho Corporation Capital Expenditure
Year Capital Expenditure Growth
1991 1.800.000
1992 8.900.000 79.78%
1993 1.900.000 -368.42%
1994 2.500.000 24%
1995 1.900.000 -31.58%
1996 5.100.000 62.75%
1997 4.200.000 -21.43%
1998 4.200.000 0%
2000 3.368.000 -24.7%
2001 5.700.000 40.91%
2002 4.263.000 -33.71%
2003 2.494.000 -70.93%
2004 5.438.000 54.14%
2005 3.157.000 -72.25%
2006 10.969.000 71.22%
2007 3.749.000 -192.58%
2008 4.478.000 16.28%
2009 7.100.000 36.93%
2010 10.477.000 32.23%
2011 20.787.000 49.6%
2012 27.722.000 25.02%
2013 22.501.000 -23.2%
2014 11.241.000 -100.17%
2015 17.032.000 34%
2016 11.909.000 -43.02%
2017 17.510.000 31.99%
2018 31.689.000 44.74%
2019 27.229.000 -16.38%
2020 64.927.000 58.06%
2021 292.724.000 77.82%
2022 140.900.000 -107.75%
2023 0 0%
2023 209.300.000 100%
2024 35.300.000 -492.92%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

QuidelOrtho Corporation Equity
Year Equity Growth
1985 15.900.000
1986 8.800.000 -80.68%
1987 1.900.000 -363.16%
1988 -400.000 575%
1989 -400.000 0%
1990 7.100.000 105.63%
1991 9.500.000 25.26%
1992 10.900.000 12.84%
1993 22.300.000 51.12%
1994 23.900.000 6.69%
1995 25.700.000 7%
1996 35.200.000 26.99%
1997 36.900.000 4.61%
1998 44.700.000 17.45%
2000 58.307.000 23.34%
2001 60.409.000 3.48%
2002 62.756.000 3.74%
2003 89.780.000 30.1%
2004 90.185.000 0.45%
2005 87.243.000 -3.37%
2006 103.276.000 15.52%
2007 107.703.000 4.11%
2008 119.236.000 9.67%
2009 126.450.000 5.71%
2010 112.521.000 -12.38%
2011 185.386.000 39.3%
2012 199.780.000 7.2%
2013 223.522.000 10.62%
2014 245.011.000 8.77%
2015 218.676.000 -12.04%
2016 200.630.000 -8.99%
2017 227.104.000 11.66%
2018 425.584.000 46.64%
2019 559.820.000 23.98%
2020 1.332.703.000 57.99%
2021 1.929.362.000 30.93%
2022 4.934.600.000 60.9%
2023 4.966.700.000 0.65%
2023 5.005.900.000 0.78%
2024 3.173.500.000 -57.74%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

QuidelOrtho Corporation Assets
Year Assets Growth
1985 17.500.000
1986 14.300.000 -22.38%
1987 5.700.000 -150.88%
1988 5.800.000 1.72%
1989 6.000.000 3.33%
1990 22.600.000 73.45%
1991 19.100.000 -18.32%
1992 21.200.000 9.91%
1993 32.900.000 35.56%
1994 34.500.000 4.64%
1995 33.300.000 -3.6%
1996 42.300.000 21.28%
1997 47.800.000 11.51%
1998 52.600.000 9.13%
2000 82.032.000 35.88%
2001 82.393.000 0.44%
2002 82.593.000 0.24%
2003 117.425.000 29.66%
2004 112.691.000 -4.2%
2005 113.848.000 1.02%
2006 127.048.000 10.39%
2007 133.838.000 5.07%
2008 142.808.000 6.28%
2009 167.697.000 14.84%
2010 214.593.000 21.85%
2011 278.894.000 23.06%
2012 241.649.000 -15.41%
2013 271.366.000 10.95%
2014 451.550.000 39.9%
2015 406.505.000 -11.08%
2016 388.250.000 -4.7%
2017 935.251.000 58.49%
2018 806.371.000 -15.98%
2019 910.867.000 11.47%
2020 1.871.164.000 51.32%
2021 2.430.374.000 23.01%
2022 8.855.800.000 72.56%
2023 8.539.100.000 -3.71%
2023 8.563.100.000 0.28%
2024 6.689.200.000 -28.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

QuidelOrtho Corporation Liabilities
Year Liabilities Growth
1985 1.600.000
1986 5.500.000 70.91%
1987 3.800.000 -44.74%
1988 6.200.000 38.71%
1989 6.400.000 3.13%
1990 15.500.000 58.71%
1991 9.600.000 -61.46%
1992 10.300.000 6.8%
1993 10.600.000 2.83%
1994 10.600.000 0%
1995 7.600.000 -39.47%
1996 7.100.000 -7.04%
1997 10.900.000 34.86%
1998 7.900.000 -37.97%
2000 23.725.000 66.7%
2001 21.984.000 -7.92%
2002 19.837.000 -10.82%
2003 27.645.000 28.24%
2004 22.506.000 -22.83%
2005 26.605.000 15.41%
2006 23.772.000 -11.92%
2007 26.135.000 9.04%
2008 23.572.000 -10.87%
2009 41.247.000 42.85%
2010 102.072.000 59.59%
2011 93.508.000 -9.16%
2012 41.869.000 -123.33%
2013 47.844.000 12.49%
2014 206.539.000 76.84%
2015 187.829.000 -9.96%
2016 187.620.000 -0.11%
2017 708.147.000 73.51%
2018 380.787.000 -85.97%
2019 351.047.000 -8.47%
2020 538.461.000 34.81%
2021 501.012.000 -7.47%
2022 3.921.200.000 87.22%
2023 3.572.400.000 -9.76%
2023 3.557.200.000 -0.43%
2024 3.515.700.000 -1.18%

QuidelOrtho Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
42.21
Net Income per Share
-27.71
Price to Earning Ratio
-1.52x
Price To Sales Ratio
1x
POCF Ratio
121.41
PFCF Ratio
-16.66
Price to Book Ratio
0.89
EV to Sales
1.94
EV Over EBITDA
15.85
EV to Operating CashFlow
235.98
EV to FreeCashFlow
-32.32
Earnings Yield
-0.66
FreeCashFlow Yield
-0.06
Market Cap
2,83 Bil.
Enterprise Value
5,50 Bil.
Graham Number
171.72
Graham NetNet
-40.76

Income Statement Metrics

Net Income per Share
-27.71
Income Quality
-0.01
ROE
-0.45
Return On Assets
-0.28
Return On Capital Employed
0.01
Net Income per EBT
0.94
EBT Per Ebit
-47.3
Ebit per Revenue
0.01
Effective Tax Rate
0.06

Margins

Sales, General, & Administrative to Revenue
0.06
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.42
Operating Profit Margin
0.01
Pretax Profit Margin
-0.7
Net Profit Margin
-0.66

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.01
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.35
Free CashFlow per Share
-2.54
Capex to Operating CashFlow
8.3
Capex to Revenue
0.07
Capex to Depreciation
0.42
Return on Invested Capital
0.01
Return on Tangible Assets
-0.6
Days Sales Outstanding
64.08
Days Payables Outstanding
52.73
Days of Inventory on Hand
133.72
Receivables Turnover
5.7
Payables Turnover
6.92
Inventory Turnover
2.73
Capex per Share
2.88

Balance Sheet

Cash per Share
1,59
Book Value per Share
47,30
Tangible Book Value per Share
-5.89
Shareholders Equity per Share
47.3
Interest Debt per Share
41.15
Debt to Equity
0.82
Debt to Assets
0.39
Net Debt to EBITDA
7.68
Current Ratio
1.44
Tangible Asset Value
-0,40 Bil.
Net Current Asset Value
-2,17 Bil.
Invested Capital
5481300000
Working Capital
0,41 Bil.
Intangibles to Total Assets
0.53
Average Receivables
0,49 Bil.
Average Payables
0,24 Bil.
Average Inventory
592550000
Debt to Market Cap
0.91

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

QuidelOrtho Corporation Dividends
Year Dividends Growth

QuidelOrtho Corporation Profile

About QuidelOrtho Corporation

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

CEO
Mr. Brian J. Blaser
Employee
7.100
Address
9975 Summers Ridge Road
San Diego, 92121

QuidelOrtho Corporation Executives & BODs

QuidelOrtho Corporation Executives & BODs
# Name Age
1 Ms. Juliet C. Cunningham
Vice President of Investor Relations
70
2 Ms. Tamara A. Ranalli
Molecular Diagnostics Business Unit Leader
70
3 Mr. Brian J. Blaser
President, Chief Executive Officer & Director
70
4 Mr. Ronald Lee Bowman
Chief Human Resources Officer
70
5 Mr. Joseph M. Busky CPA
Chief Financial Officer
70
6 Mr. Michael S. Iskra
Executive Vice President & Chief Commercial Officer
70
7 Mr. Robert J. Bujarski J.D.
Executive Vice President & Chief Operating Officer
70
8 Dr. Werner Kroll Ph.D.
Senior Vice President of Research & Development
70
9 Ms. Michelle A. Hodges J.D.
Senior Vice President, General Counsel & Corporate Secretary
70
10 Mr. William J. Ferenczy
Point of Care Business Unit Leader
70

QuidelOrtho Corporation Competitors

DexCom, Inc. Logo
DexCom, Inc.

DXCM

(2.2)
Penumbra, Inc. Logo
Penumbra, Inc.

PEN

(2.0)
NuVasive, Inc. Logo
NuVasive, Inc.

NUVA

(1.0)
Glaukos Corporation Logo
Glaukos Corporation

GKOS

(0.5)
CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Masimo Corporation Logo
Masimo Corporation

MASI

(1.0)
Inari Medical, Inc. Logo
Inari Medical, Inc.

NARI

(1.8)
Insulet Corporation Logo
Insulet Corporation

PODD

(2.0)
STERIS plc Logo
STERIS plc

STE

(2.8)
Bruker Corporation Logo
Bruker Corporation

BRKR

(2.5)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
SI-BONE, Inc. Logo
SI-BONE, Inc.

SIBN

(1.0)
NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)